Katrina Armstrong, MD, MSCE, discusses latest results of the STAR trial on breast cancer risk reduction with Raloxifene and Tamoxifen

April 21, 2010

NCI Cancer Bulletin

Katrina Armstrong, MD, MSCE, chief of the division of General Internal Medicine and co-director of the Cancer Control Program in the Abramson Cancer Center, is quoted in an NCI Cancer Bulletin story reporting on the high risk of the disease. The findings add to "the evidence that supports the long-term benefits of these drugs," Armstrong said, but clinicians and researchers must now focus on the barriers to the use of the drugs and find ways to identify women who are eligible to take them and make decisions about which drug is more appropriate. To help clinicians discuss breast cancer chemoprevention options with patients, Armstrong and her colleagues are developing decision-support tools to disseminate to primary care practices to assess a patient's risk and link it with a decision-support tool built into the center's electronic medical record system. The hope, Armstrong says, "is that we can get to a point where we can say that these are the women who will receive the greatest benefit from raloxifene or tamoxifen; they are way over the threshold for absolute benefit and should be offeredthe medication." Read More